Masimo Co. (NASDAQ:MASI) Shares Acquired by Baird Financial Group Inc.

Baird Financial Group Inc. increased its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 369.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 34,198 shares of the medical equipment provider's stock after purchasing an additional 26,914 shares during the quarter. Baird Financial Group Inc. owned 0.06% of Masimo worth $5,653,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its holdings in Masimo by 17.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 31,107 shares of the medical equipment provider's stock valued at $5,142,000 after acquiring an additional 4,579 shares in the last quarter. Lecap Asset Management Ltd. acquired a new stake in shares of Masimo in the fourth quarter valued at approximately $1,607,000. Nisa Investment Advisors LLC increased its stake in shares of Masimo by 16,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider's stock worth $835,000 after purchasing an additional 5,022 shares in the last quarter. Trust Point Inc. acquired a new position in shares of Masimo during the 4th quarter worth approximately $230,000. Finally, Barclays PLC lifted its stake in Masimo by 152.6% in the 3rd quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock valued at $5,329,000 after buying an additional 24,137 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Masimo Stock Performance

Shares of MASI stock opened at $157.18 on Friday. The firm has a market capitalization of $8.49 billion, a price-to-earnings ratio of 108.40 and a beta of 1.23. The company has a 50 day moving average price of $161.66 and a 200 day moving average price of $166.58. Masimo Co. has a one year low of $101.61 and a one year high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $372.00 million for the quarter, compared to analysts' expectations of $367.79 million. During the same quarter last year, the firm earned $0.77 earnings per share. The firm's revenue for the quarter was down 24.5% compared to the same quarter last year. Sell-side analysts anticipate that Masimo Co. will post 4.1 EPS for the current year.

Analysts Set New Price Targets

MASI has been the subject of several recent research reports. BTIG Research set a $193.00 price target on Masimo and gave the stock a "buy" rating in a research report on Wednesday. Raymond James reduced their target price on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a report on Wednesday. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Wells Fargo & Company reduced their price objective on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research note on Wednesday. Finally, Piper Sandler restated an "overweight" rating and set a $200.00 target price (down previously from $215.00) on shares of Masimo in a research report on Wednesday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $191.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.